WEDNESDAY, Feb. 16 (HealthDay News) -- A new study holds
potentially good news for preterm infants who develop an eye
condition that may cause blindness: An inexpensive drug appears to
do a better job of treating the condition than the existing
Just 4 percent of babies treated with the cancer drug Avastin
suffered a recurrence of retinopathy of prematurity, a disease that
harms the retina. By contrast, it recurred in 22 percent of those
who received laser treatment to combat the condition, which is the
most common cause of blindness in infants.
The treatment, given by injection in the eye, costs $40 for both
eyes and doesn't need an eye doctor on hand, making it a good
option for poor countries where the disease is more common, said
study author Dr. Helen A. Mintz-Hittner, a pediatric
ophthalmologist at the University of Texas Health Science Center at
"You're paying $40 for a pair of eyes for 80 years," Mintz-Hittner said, referring to the lifespan of patients who may avoid blindness. "You can't get much more bang for your buck than that. It's really a major advance."
Retinopathy of prematurity most commonly occurs in babies born
extremely prematurely who receive oxygen treatment after birth. In
some cases, babies get too much oxygen and the lungs fail to
deliver it properly to the body, depriving tissues in the
developing eye, explained Dr. James D. Reynolds, chair of the
department of ophthalmology at the University at Buffalo, who wrote
a commentary accompanying the study.
"We try the best we can to duplicate the in-utero conditions, but obviously we cannot," he said. As the baby grows after birth, the developing eye can be damaged as blood vessels grow abnormally; the retinas detach in some of the infants months after birth and may result in blindness.
Laser treatment can stop the progress toward blindness, but it
also may cause infants to lose peripheral vision and suffer from
poor overall vision, Mintz-Hittner said. As adults, "they're not
able to see off to the side, they have very thick glasses, and it's
hard for them to drive," she said.
The study is published in the Feb. 17 issue of the
New England Journal of Medicine.
Avastin (bevacizumab), is best known as a chemotherapy drug, but
it's also used to treat eye disease. The researchers tested either
the drug or laser therapy on 143 infants and found that it worked
well on babies with one type of the disease.
The drug works by blocking the abnormal growth of blood vessels,
Reynolds said. "We are going to save some babies who would have
gone blind with the laser treatment," Reynolds said. "It will
change the patterns of practice overnight."
Timing of the injections is critical to the drug's success, the
authors noted, and more research is necessary to determine the
appropriate dose for different forms of the disease.
The U.S. Food and Drug Administration recently announced a plan
to rescind its conditional approval of Avastin for treating breast
cancer after serious side effects were noted in some patients and
recent studies failed to show survival benefit.
Addressing safety concerns, the authors of this study said no
ill effects were seen and that the dose used in the eye is only a
fraction of that needed for cancer treatment.
However, because of the small size of their study, they
recommend ongoing monitoring of children injected with Avastin to
watch for any systemic effects.
The study was funded by the Research to Prevent Blindness, the
U.S. National Eye Institute and other non-industry sources.
For more about
retinopathy of prematurity, see the U.S. National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.